Cancer Research and Treatment is a premier academic journal published by the Korean Cancer Association that focuses on advancing scientific knowledge and clinical practices in the fields of cancer research and oncology. With an ISSN of 1598-2998 and an E-ISSN of 2005-9256, the journal showcases cutting-edge research articles, clinical trials, and comprehensive reviews that address the multifaceted challenges in cancer treatment and management. Published in South Korea, this journal has established itself as a critical resource, evidenced by its Q1 rank in Oncology and Q2 rank in Cancer Research, reflecting its influence and stature within the academic community. The impact of research disseminated through Cancer Research and Treatment is underscored by its significant percentile rankings in Scopus, with notable positions in both the pharmaceutical and biological sectors. This journal aims to bridge the gap between laboratory research and clinical application, providing a platform for researchers, healthcare professionals, and students to enhance their understanding of cancer-related innovations and therapeutic strategies. Readers will benefit from rich content that not only discusses the latest advancements but also engages with pressing global health issues related to cancer.

CURRENT CANCER DRUG TARGETS is a prominent academic journal published by Bentham Science Publishers Ltd, focusing on the critical intersection of cancer research and innovative drug development. Since its inception in 2001, this journal has offered a platform for the dissemination of cutting-edge research aimed at advancing targeted cancer therapies, contributing significantly to the fields of Cancer Research, Drug Discovery, Oncology, and Pharmacology. With a respectable impact factor and consistent ranking in its respective categories, including Q2 in Drug Discovery and Pharmacology, it positions itself as an invaluable resource for researchers, clinicians, and students alike. CURRENT CANCER DRUG TARGETS is dedicated to enhancing our understanding of novel therapeutic targets and methods, thereby fostering a collaborative environment for knowledge exchange in the ever-evolving landscape of cancer treatment.

BioChip Journal, published by the Korean Biochip Society (KBCS), is a renowned academic platform dedicated to advancing the fields of bioengineering, biomedical engineering, biotechnology, and electrical and electronic engineering. With its ISSN 1976-0280 and E-ISSN 2092-7843, this esteemed journal has established itself as a valuable resource for researchers, professionals, and students alike, providing them with cutting-edge research and insights since its inception in 2008. The journal has earned a commendable standing in the academic community, achieving Q2 ranking across key categories, thereby placing it amongst the top-tier publications. With its impressive Scopus rankings, including a top 10% position in Electrical and Electronic Engineering and a strong showing in both Biomedical Engineering and Biotechnology, BioChip Journal plays a vital role in disseminating innovative biochip technologies and applications. The journal continues to invite groundbreaking studies and reviews that promote the interdisciplinary collaboration essential for the future of biochip research, ultimately contributing to advancements in healthcare, diagnostics, and therapeutics.

Journal of Reports in Pharmaceutical Sciences is a pivotal publication in the realm of pharmaceutical research, disseminating innovative findings that cater to the evolving landscape of pharmacology, toxicology, and biomedical engineering. Published by Wolters Kluwer Medknow Publications, the journal serves as a bridge for scholars and practitioners aiming to enhance their understanding of drug development, therapeutic advances, and biopharmaceutical technologies. With an ISSN of 2322-1232 and E-ISSN 2322-5106, it has established its relevance from 2012 to 2022, occupying notable quartile rankings, including Q3 in Pharmacology, Toxicology, and Pharmaceutics. Despite being categorized in Q4 in some areas, the journal's commitment to quality research ensures it remains a respected platform for disseminating significant insights. Researchers, professionals, and students alike will find this journal an indispensable resource for staying updated on critical advancements in pharmaceutical sciences, making it a go-to source for impactful studies that shape industry practices and academic inquiries.

DRUG DELIVERY is a premier academic journal published by TAYLOR & FRANCIS LTD, with a steadfast commitment to advancing research in the fields of medicine and pharmaceutical sciences. As an Open Access journal since 2017, it offers unparalleled accessibility to its high-quality content, making it an invaluable resource for researchers, professionals, and students alike. With an impressive 2023 impact factor, it ranks in the Q1 quartile for both Medicine (miscellaneous) and Pharmaceutical Science, evidencing its significant impact within the scientific community. The journal focuses on innovative drug delivery systems, therapeutics, and methodologies that enhance patient care and treatment options. Based in the United Kingdom, it has evolved since its inception in 1993 to create a richly diverse platform for scholarly dialogue and advancements in the pharmaceutical landscape. Researchers looking to stay at the forefront of drug delivery research will find DRUG DELIVERY an essential companion in their pursuits.

JOURNAL OF DRUG TARGETING, published by Taylor & Francis Ltd, is a premier academic journal dedicated to advancing the field of pharmaceutical sciences with a strong focus on drug delivery and targeting methodologies. With an impressive impact factor and recognized as a Q1 journal in the Pharmaceutical Science category, it ranks #23 out of 183 in Pharmacology, Toxicology and Pharmaceutics, placing it within the top 13% of journals in its field. The journal provides a platform for interdisciplinary research, showcasing innovative techniques and breakthrough findings that serve to improve therapeutic efficacy through precision targeting. Although it operates under a subscription model, researchers benefit from extensive access to pivotal studies spanning from 1986 to 2024. The JOURNAL OF DRUG TARGETING aims to foster collaboration among academics, professionals, and students, making it an essential resource for those seeking to leverage the latest advancements in drug development and delivery systems for improved healthcare outcomes.

Theranostics is a premier journal in the field of Medicine and Pharmacology, published by IVYSPRING INT PUBL. With its commitment to open access since 2011, it facilitates the widespread dissemination of innovative research, fostering collaboration and advancements in therapeutic diagnostics. The journal proudly holds a Q1 ranking in both Medicine (Miscellaneous) and Pharmacology, Toxicology and Pharmaceutics, as of 2023, showcasing its esteemed position within the scientific community. Recognized globally, it ranks in the top 1%, with Scopus rankings placing it as 4th out of 398 in Medicine and 1st out of 43 in Pharmacology. Theranostics serves as a crucial platform for researchers, professionals, and students to explore cutting-edge developments as it converges multidisciplinary approaches to enhance patient care and treatment efficacy. With a focus on bridging experimental research and clinical applications, the journal is instrumental in shaping future therapies and diagnostic strategies.

Nanomedicine, published by Future Medicine Ltd, is a premier academic journal dedicated to the rapidly evolving field of nanotechnology in medicine. With an emphasis on innovative research and applications, this journal encompasses a broad spectrum of topics including bioengineering, biomedical engineering, and nanoscience, among others. Featuring an impressive Q1 ranking in Development and multiple Q2 rankings across significant categories, it serves as a pivotal resource for researchers and professionals aiming to stay at the forefront of advancements in these disciplines. While the journal is not open access, it is accessible through various institutional subscriptions, ensuring wide dissemination of cutting-edge findings. Notably, it has achieved substantial impact within the scientific community, indicated by its high rankings in Scopus and overall commitment to enhancing the understanding and application of nanomedicine. This journal is a vital conduit for fostering collaborations and innovations that transcend traditional medical paradigms.

Nano LIFE, published by World Scientific Publishing Company, is a multidisciplinary journal that delves into the dynamic fields of bioengineering, biomedical engineering, and pharmaceutical science, providing a platform for researchers to disseminate their cutting-edge findings. With an ISSN of 1793-9844 and e-ISSN 1793-9852, this journal emphasizes the significance of nanoscale research in healthcare and technology, positioning itself as a vital resource for professionals and academics alike. Although currently categorized in the Q4 quartile for multiple scientific disciplines in 2023, its unique focus on the intersection of nanotechnology and life sciences aims to elevate the discourse in these rapidly evolving sectors. Researchers can anticipate publishing innovative methodologies and results, contributing to the overall understanding and application of nanotechnology in medicine. Located in Singapore, Nano LIFE not only serves the global research community but also reflects the growing interest in nanotechnology across diverse fields.

JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE is a leading peer-reviewed journal published by Springer, dedicated to advancing the field of biomedical materials science. With an ISSN of 0957-4530 and E-ISSN 1573-4838, this Open Access journal has been committed to providing researchers and professionals with freely accessible, high-quality research since 2021. It features an extensive scope spanning bioengineering, biomaterials, biomedical engineering, and biophysics, reflecting its significant impact within these interdisciplinary domains. Recognized within the Q2 category of the 2023 rankings in multiple fields, the journal proudly positions itself as a crucial resource for innovative materials that contribute to advancements in medical applications. With impressive Scopus rankings, including 26th in Biophysics and 40th in Materials Science for Biomaterials, researchers, students, and industry professionals alike can rely on this publication for cutting-edge insights that drive the future of medical materials and technologies. Based in Dordrecht, Netherlands, the journal provides a vibrant platform for sharing groundbreaking discoveries and fostering collaborative research among a global audience.